The milestone was due to the initiation of a phase 3 trial evaluating the efficacy and safety of the retifanlimab with platinum-based chemotherapy in patients with metastatic squamous and non-squamous non-small cell lung cancer.
Under the agreement, MacroGenics can receive up to $390 million and $330 million in potential remaining development and regulatory milestones and commercial milestones, respectively. The company can also receive royalties, tiered from 15% to 24%, on future global sales.
Price: 27.65, Change: -3.95, Percent Change: -12.50
|Significant Insider Sales Reported in Shares of KalV...|
|Insider Sale at Mastercard (MA) Continues Selling Trend|
|Insider Selling at Illumina (ILMN) Continues with Si...|
|Insider Selling in Salesforce.com (CRM) Shares Conti...|
|VeriSign (VRSN) sees Significant Insider Sales Exten...|